Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234495 | 0.90 | AVPR2 (0.78) | AVPR2 | |
| SCHEMBL6627425 | 0.88 | AVPR2 (0.80) | AVPR2 | |
| SCHEMBL5234519 | 0.86 | AVPR2 (0.77) | AVPR2 | |
| SCHEMBL5267294 | 0.86 | AVPR2 (1.00) | AVPR2 | |
| SCHEMBL6625761 | 0.85 | AVPR2 (0.79) | AVPR2 | |
| SCHEMBL5232674 | 0.84 | AVPR2 (0.75) | AVPR2 | |
| SCHEMBL6625979 | 0.84 | AVPR2 (0.81) | AVPR2 | |
| SCHEMBL6625567 | 0.84 | AVPR2 (0.77) | AVPR2 | |
| SCHEMBL5232864 | 0.84 | AVPR2 (1.00) | AVPR2 | |
| SCHEMBL8269476 | 0.83 | AVPR2 (0.70) | AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1226122-B1 | BICYCLIC VASOPRESSIN AGONISTS | FERRING BV (NL) | 2004-12-15 | — | — | EP | claimed |
| US-6664249-B1 | Such as 1-(4-(N-(4-methoxy-4-oxobutanoyl)aminomethyl)-3-methylbenzoyl)-2, 3,4,5-tetrahydro-1H-1-benzazepine; polyuria | FERRING BV (NL) | 2003-12-16 | — | — | US | claimed |
| EP-1226122-A1 | BICYCLIC VASOPRESSIN AGONISTS | Ferring BV (NL) | 2002-07-31 | — | — | EP | claimed |
| WO-2001029005-A1 | BICYCLIC VASOPRESSIN AGONISTS | FERRING BV (NL) | 2001-04-26 | — | — | WO | claimed |
| EP-1294698-B1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING BV (NL) | 2007-08-01 | — | — | EP | disclosed |
| EP-1294698-B1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING BV (NL) | 2007-08-01 | — | — | EP | disclosed |
| US-7176195-B2 | Fused azepine derivatives and their use as antidiuretic agents | FERRING BV (NL) | 2007-02-13 | — | — | US | disclosed |
| US-7176195-B2 | Fused azepine derivatives and their use as antidiuretic agents | FERRING BV (NL) | 2007-02-13 | — | — | US | disclosed |
| US-7176195-B2 | Fused azepine derivatives and their use as antidiuretic agents | FERRING BV (NL) | 2007-02-13 | — | — | US | disclosed |
| EP-1226122-B1 | BICYCLIC VASOPRESSIN AGONISTS | FERRING BV (NL) | 2004-12-15 | — | — | EP | disclosed |
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | VANTIA LIMITED (GB) | 2004-02-26 | — | — | US | disclosed |
| US-6664249-B1 | Such as 1-(4-(N-(4-methoxy-4-oxobutanoyl)aminomethyl)-3-methylbenzoyl)-2, 3,4,5-tetrahydro-1H-1-benzazepine; polyuria | FERRING BV (NL) | 2003-12-16 | — | — | US | disclosed |
| EP-1226122-A1 | BICYCLIC VASOPRESSIN AGONISTS | Ferring BV (NL) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001029005-A1 | BICYCLIC VASOPRESSIN AGONISTS | FERRING BV (NL) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | AVPR2, AVPR1A, AVPR1B | AVPR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.